Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non–Small-Cell Lung Cancer and High PD-L1 Tumor Expression
Yuichi Tambo, Takashi Sone, Kazuhiko Shibata, Kouichi Nishi, Hiroki Shirasaki, Taro Yoneda, Tomoyuki Araya, Kazumasa Kase, Shingo Nishikawa, Hideharu Kimura, Kazuo Kasahara
Topics & Concepts
MedicinePembrolizumabInternal medicineHazard ratioLung cancerConfidence intervalInterstitial lung diseaseClinical trialAdverse effectResponse Evaluation Criteria in Solid TumorsOncologyProgression-free survivalGastroenterologyCancerLungPhases of clinical researchChemotherapyImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations